Deal Team

Corporate

Pfizer in its sale of 700 million ordinary shares in Haleon to institutional investors

On January 15, 2025, Pfizer Inc. (NYSE: PFE) announced the sale of 700 million ordinary shares in Haleon plc (LSE/NYSE: HLN) to institutional investors in an unregistered offering pursuant to exemptions from registration under the Securities Act of 1933, at a price of 357 pence ($4.36) per ordinary share.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Pfizer.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.